THE BEST SIDE OF JOURNAL OF CLINICAL BREAST CANCER

Genomic sequencing Investigation of 733 HER2-amplified Major and metastatic breast tumours exposed important enrichment of mutations that activate RAS–MAPK signalling in Sophisticated tumours handled with prior anti-HER2 therapies121. These mutations, which include NF1 and HER2 activating mutations, add to resistance to tucatinib and neratinib.In